Medicine and Dentistry
Cytoreductive Surgery
100%
Hyperthermic Intraperitoneal Chemotherapy
87%
Overall Survival
68%
Adenocarcinoma
45%
Abdominal Cancer
42%
Neoplasm
39%
Malignant Neoplasm
34%
Diseases
25%
Surgery
24%
Cancer
23%
Recurrent Disease
22%
Carcinomatous Peritonitis
21%
Appendix Tumor
16%
Hazard Ratio
16%
Peritoneum Metastasis
15%
Gastrectomy
15%
Intraperitoneal Chemotherapy
15%
Peritoneum Mesothelioma
12%
Recurrence Free Survival
11%
Lymph Node
11%
Colorectal Carcinoma
10%
Patient Selection
10%
Chemoradiation Therapy
10%
Signet Ring Cell
10%
Stomach Adenocarcinoma
10%
Postoperative Complication
9%
Disease Free Survival
9%
Multivariate Analysis
9%
Tumor Marker
9%
Progression Free Survival
9%
Lymph Node Metastasis
8%
Odds Ratio
8%
Metastatic Carcinoma
8%
Peritoneum Cancer
8%
Carcinoembryonic Antigen
7%
Laparoscopic Surgery
7%
Percutaneous Coronary Intervention
6%
Survival Rate
6%
Cytotechnology
6%
Mucinous Carcinoma
6%
Mesothelioma
6%
Retrospective Study
6%
Computer Assisted Tomography
5%
Colon Carcinoma
5%
Proportional Hazards Model
5%
Primary Tumor
5%
Long Term Survival
5%
Carcinosis
5%
Chemoradiotherapy
5%
Keyphrases
Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
79%
Cytoreductive Surgery
51%
Overall Survival
41%
Appendiceal Adenocarcinoma
30%
Gastric Cancer
30%
Tumor
12%
Confidence Interval
12%
Hazard Ratio
12%
Preoperative Therapy
12%
Appendiceal
11%
Chemotherapy
11%
Gastrectomy
11%
Peritoneal Carcinomatosis
11%
Resection
11%
Gastric Adenocarcinoma
10%
Patient Selection
10%
Secondary Cytoreductive Surgery
10%
Non-associated
9%
Peritoneal Cancer Index
9%
Peritoneal Metastasis
9%
Preoperative Chemoradiation Therapy
9%
Appendiceal Cancer
9%
Postoperative Outcomes
9%
Appendiceal Neoplasms
9%
Progression-free Survival
8%
Carbohydrate Antigen 19-9 (CA19-9)
7%
Recurrence-free Survival
7%
United States
7%
Malignant Peritoneal Mesothelioma
7%
Multi-institutional Analysis
7%
Multivariate Analysis
7%
Colorectal Cancer
6%
Postoperative Complications
6%
Systemic Chemotherapy
6%
Lymph Node
6%
Tumor Marker
6%
Cytoreduction
6%
Peritoneal Surface Malignancy
6%
5-year Survival
6%
Hyperthermia
5%
Multi-institutional
5%
Histology
5%
Signet Ring Cell
5%
Poor Differentiation
5%
Gastric Cancer Patients
5%
Disease-free Survival
5%